Stage IV Melanoma


Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential.... Continue Reading

President Jimmy Carter Will Undergo Treatment for Melanoma (August 20, 2015)

Former President Jimmy Carter has melanoma and will begin undergoing radiation treatment today for four melanoma tumors in his brain, he told reporters at the Carter Center in Atlanta. Skin cancer is the... Continue Reading

New Combination Treatment Effective Against Melanoma Skin Metastases (August 18, 2015)

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown. Led by Emanual Maverakis... Continue Reading

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma (June 29, 2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual... Continue Reading

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings... Continue Reading

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is... Continue Reading

Final Budget Bill Doubles DoD Funding Available for Melanoma Research (December 11, 2014)

The Melanoma Research Alliance (MRA) hailed the inclusion in the omnibus appropriations bill providing government funding for Fiscal Year 2015 of $50 million in funding for the Department of Defense’s... Continue Reading

References (December 9, 2014)

1 Cancer Facts & Figures 2013. American Cancer Society website. Available at:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed January... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS